All In Biotech

Drug Trial Radar · NCT04644029

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection

Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 730 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

730

Actual

Start

Feb 24, 2021

Primary completion

Jul 18, 2023

Study completion Jun 11, 2024

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 16 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate whether oral islatravir (ISL) is effective in preventing Human Immunodeficiency Virus Type 1 (HIV-1) infection in women at high-risk for HIV-1 infection. The study will compare oral ISL taken once a month with standard-of-care medication for prevention of HIV-1 infection, emtricitabine/tenofovir disoproxil (FTC/TDF), taken once per day. The primary hypothesis is that oral ISL is more effective than FTC/TDF at reducing the incidence rate per year of confirmed HIV-1 infections.

Conditions

  • HIV-I
  • Human Immunodeficiency Virus Type 1
  • Prophylaxis

Interventions

  • IslatravirDrug

    Oral 60 mg tablet administered once monthly during Part 1.

  • Placebo to FTC/TDFDrug

    0 mg tablet administered once daily during Part 1.

  • FTC/TDFDrug

    Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate), administered orally once daily in Parts 1, 2, and 3.

  • Placebo to ISLDrug

    0 mg tablet administered orally once monthly in Part 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Rate Per Year of Confirmed HIV-1 Infection Among Participants During Blinded Treatment +42 Days Post-BlindTime frame: Up to approximately 325 days
  2. Number of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment + 42 Days Post-BlindTime frame: Up to approximately 325 days
  3. Number of Participants Who Discontinued Blinded Study Treatment Due to an AETime frame: Up to 283 days

Locations

24 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham-UAB Sexual Health Research Clinic (SHRC) ( Site 0064)

    Birmingham, Alabama

  • MedStar Health Research Institute (MedStar Physician Based R-MedStar Washington Hospital Center ( Si

    Washington D.C., District of Columbia

  • University of Miami Miller School of Medicine-Infectious Disease ( Site 0076)

    Miami, Florida

  • Orlando Immunology Center ( Site 0068)

    Orlando, Florida

  • Ponce De Leon Center Grady Health ( Site 0066)

    Atlanta, Georgia

  • The University of Mississippi Medical Center ( Site 0065)

    Jackson, Mississippi

  • KC CARE Health Center-Clinical Trials ( Site 0059)

    Kansas City, Missouri

  • Rutgers New Jersey Medical School-Clinical Research Center ( Site 0071)

    Newark, New Jersey

  • Bronx Prevention Center ICAP ( Site 0062)

    The Bronx, New York

  • The University of North Carolina at Chapel Hill-Medicine ( Site 0056)

    Chapel Hill, North Carolina

  • Prisma Health Richland Hospital-Clinical Research Unit ( Site 0069)

    Columbia, South Carolina

  • Prism Health North Texas, Oak Cliff Health Center ( Site 0070)

    Dallas, Texas

  • West Virginia University-Department of Medicine ( Site 0061)

    Morgantown, West Virginia

  • Perinatal HIV Research Unit (PHRU)-HIV Prevention CRS ( Site 0023)

    Johannesburg, Gauteng, South Africa

  • Wits Reproductive Health and HIV Institute (WRHI)-Wits RHI Ward 21 Clinical Research site ( Site 002

    Johannesburg, Gauteng, South Africa

  • Helen Joseph Hospital-Clinical HIV Research Unit ( Site 0020)

    Johannesburg, Gauteng, South Africa

  • Setshaba Research Centre ( Site 0016)

    Pretoria, Gauteng, South Africa

  • SA Medical Research Council - Chatsworth Clinical Research Site ( Site 0030)

    Chatsworth, KwaZulu-Natal, South Africa

  • Maternal Adolescent and Child Health Research (MatCH) ( Site 0025)

    Durban, KwaZulu-Natal, South Africa

  • Qhakaza Mbokodo Research Clinic ( Site 0017)

    Ladysmith, KwaZulu-Natal, South Africa

  • Madibeng Centre for Research ( Site 0019)

    Brits, North West, South Africa

  • Aurum Institute Klerksdorp CRS ( Site 0029)

    Klerksdorp, North West, South Africa

  • Aurum Institute - Rustenburg ( Site 0022)

    Rustenburg, North West, South Africa

  • MU-JHU Care Limited-Clinic ( Site 0041)

    Kampala, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.